Target intelligence / Profile preview

Cytosine deaminase (CDA) (CDA)

Target
CDA
Molecular classification
Enzyme, Hydrolase, Amidohydrolase superfamily
01

Overview

Cytosine deaminase (CDA) is an enzyme that catalyzes the hydrolytic deamination of cytosine to uracil and ammonia. It is primarily found in bacteria and fungi and is notably absent in higher eukaryotes, including humans. This absence makes CDA a valuable tool in suicide gene therapy for cancer, where the enzyme is delivered to tumor cells to convert the non-toxic prodrug 5-fluorocytosine (5-FC) into the potent chemotherapeutic 5-fluorouracil (5-FU). Phosphonocytosine is a well-known transition state analog and potent inhibitor of this enzyme, used to study its catalytic mechanism and structural biology. By mimicking the tetrahedral intermediate of the reaction, phosphonocytosine provides insights into the active site architecture, facilitating the engineering of CDA variants with improved therapeutic properties.

Other names
Cytosine aminohydrolaseCodAbCDyCDCytosine deaminase (CDA)
02

Mechanism of action

Cytosine deaminase converts the prodrug 5-fluorocytosine into 5-fluorouracil, which is then converted to 5-FdUMP, a suicide inhibitor of thymidylate synthase, thereby inhibiting DNA synthesis and inducing apoptosis.

03

Biological functions

Nucleobase metabolismPyrimidine salvageDeamination
04

Disease associations

CancerInfection
05

Safety considerations

Bystander effect toxicityOff-target prodrug conversion by gut microbiotaImmunogenicity of non-human enzyme
06

Interacting drugs

5-Fluorocytosine

2 more in the full profile.

07

Biomarkers

CDA protein expression5-FU concentrationThymidylate synthase activity

Beyond the preview

Go deeper on Cytosine deaminase (CDA) (CDA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytosine deaminase (CDA) (CDA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call